Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.
about
Crizotinib resistance: implications for therapeutic strategiesThe role of the ALK receptor in cancer biologyThe steady progress of targeted therapies, promising advances for lung cancerPulmonary epithelioid inflammatory myofibroblastic sarcoma with multiple bone metastases: case report and review of literaturePreclinical mouse cancer models: a maze of opportunities and challenges.Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology GroupNCI Workshop Report: Clinical and Computational Requirements for Correlating Imaging Phenotypes with Genomics SignaturesA first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.Non-small-cell lung cancers: a heterogeneous set of diseases.Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.A co-clinical platform to accelerate cancer treatment optimization.Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancerSerum Metabolic Profile Alteration Reveals Response to Platinum-Based Combination Chemotherapy for Lung Cancer: Sensitive Patients Distinguished from Insensitive ones.Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib.A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.Autochthonous murine models for the study of smoker and never-smoker associated lung cancers
P2860
Q26738381-B49AF031-C638-4A7F-A439-F07D0E47AC01Q26738384-BE1F8D33-E18A-41F3-BC51-8E6714C3C17DQ26746895-F807B6FF-2A09-4893-BE9A-E0F6CD3B439FQ26823788-83B80374-6D0A-4941-A866-58FD51A23136Q27322080-3357904E-8E7A-4DD2-A28E-F6BABA36BF39Q33587905-19E50E4C-0505-4028-9F04-395C440DAE9DQ34478588-7FD20D70-0153-4C59-88E8-2DD448A1663CQ35098333-53F4596A-43F9-4630-984D-BCED4CBC7B3DQ35930811-04BED04C-250C-40D2-A6C1-AEDFFCB53AFBQ38233321-2B724AD3-FFD1-4EC9-AEA9-B4EAA1FF9057Q38753582-1A2669C8-5B70-46FB-AF98-36993B621D3FQ38800617-9F67551A-104B-423B-96B3-0050B02F898EQ41736028-55695A65-77C5-4D16-BD3E-BDB9B3B46847Q42039942-75CD95F2-DECC-4017-9968-571992E83B8FQ47155641-081E7F66-D179-46C0-864E-A3272B56BD03Q47671139-8648FCD7-5BA8-4EDF-BB58-E8114454561DQ50898344-3A7C9EA3-0DC8-45C1-A098-8B8886539BD6Q54198800-ED3B7FBF-0218-45EE-AE87-1DBE77ECD1D3Q58804389-5FD92270-ACF4-4933-9E32-F415CDA9F393
P2860
Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Co-clinical trials demonstrate ...... tegies to overcome resistance.
@en
type
label
Co-clinical trials demonstrate ...... tegies to overcome resistance.
@en
prefLabel
Co-clinical trials demonstrate ...... tegies to overcome resistance.
@en
P2093
P2860
P50
P1476
Co-clinical trials demonstrate ...... tegies to overcome resistance.
@en
P2093
Abigail Altabef
Geoffrey I Shapiro
Jacob B Reibel
Jeffrey A Engelman
Katherine Cheng
Liang Chen
Oliver Mikse
Pasi A Janne
Sue-Ann Woo
Tanya Tupper
P2860
P304
P356
10.1158/1078-0432.CCR-13-1733
P407
P577
2013-12-10T00:00:00Z